Literature DB >> 3985596

Antibiotic uptake by alveolar macrophages of smokers.

W L Hand, R M Boozer, N L King-Thompson.   

Abstract

Cigarette smoking, particularly when associated with chronic pulmonary disease, increases the risk of respiratory tract infection. Thus, we elevated the uptake of antibiotics by alveolar macrophages (AM) obtained by bronchoalveolar lavage from persons who smoke and have associated pulmonary abnormalities, circumstances which adversely affect certain macrophage functions. The entry of radiolabeled drugs into AM was determined by a velocity-gradient centrifugation technique, and uptake was expressed as the ratio of cellular to extracellular antibiotic concentration (C/E). Cefamandole and penicillin G were taken up poorly by the AM obtained from smokers (C/E less than or equal to 1). Cellular levels of isoniazid, gentamicin, and tetracycline were similar to their extracellular concentrations. The lipid-soluble drugs lincomycin, chloramphenicol, and rifampin were concentrated severalfold by the AM from smokers (C/E = 3 to 11). Ethambutol also entered macrophages readily (C/E = 11). Erythromycin and clindamycin were massively concentrated by the AM from smokers (C/E = 23 to 56). The AM of smokers accumulated a lipid-soluble antibiotic (rifampin) and actively transported agents (erythromycin propionate, clindamycin) more avidly than did the AM of nonsmokers. Augmented uptake of these antibiotics by the AM of smokers may be related to structural and functional alterations induced by smoking.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3985596      PMCID: PMC176202          DOI: 10.1128/AAC.27.1.42

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Comparison of proteolytic enzyme activity in pulmonary alveolar macrophages and blood leukocytes in smokers and nonsmokers.

Authors:  J O Harris; G N Olsen; J R Castle; A S Maloney
Journal:  Am Rev Respir Dis       Date:  1975-05

2.  Surface morphology of the human alveolar macrophage.

Authors:  S G Quan; D W Golde
Journal:  Exp Cell Res       Date:  1977-10-01       Impact factor: 3.905

Review 3.  The pulmonary-alveolar macrophage (second of two parts).

Authors:  W G Hocking; D W Golde
Journal:  N Engl J Med       Date:  1979-09-20       Impact factor: 91.245

4.  Pinocytosis by human alveolar macrophages. Comparison of smokers and nonsmokers.

Authors:  H Yeager; S M Zimmet; S L Schwartz
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

Review 5.  Pulmonary clearance of infectious agents.

Authors:  G M Green
Journal:  Annu Rev Med       Date:  1968       Impact factor: 13.739

6.  Adult pneumonia in a general hospital. Etiology and host risk factors.

Authors:  R J Sullivan; W R Dowdle; W M Marine; J C Hierholzer
Journal:  Arch Intern Med       Date:  1972-06

7.  The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages.

Authors:  G M Green; D Carolin
Journal:  N Engl J Med       Date:  1967-02-23       Impact factor: 91.245

8.  In vitro migration of human alveolar macrophages: effects of cigarette smoking.

Authors:  G A Warr; R R Martin
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

9.  Cell-mediated immunity after bacterial infection of the lower respiratory tract.

Authors:  J R Cantey; W L Hand
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Human alveolar macrophages: comparison of phagocytic ability, glucose utilization, and ultrastructure in smokers and nonsmokers.

Authors:  J O Harris; E W Swenson; J E Johnson
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

View more
  14 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

2.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 3.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 4.  Effects of beta-lactam antibiotics on proliferating eucaryotic cells.

Authors:  K A Neftel; U Hübscher
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

5.  Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base.

Authors:  P Villa; D Sassella; M Corada; I Bartosek
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

6.  Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations.

Authors:  J E Conte; J A Golden; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

8.  Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  J R Black; J Feinberg; R L Murphy; R J Fass; J Carey; F R Sattler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

9.  Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.

Authors:  John E Conte; Jeffrey A Golden; Juliana E Kipps; Emil T Lin; Elisabeth Zurlinden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.